ArticleFrontiers in endocrinology2025
Development of a new TNM staging system for poorly differentiated thyroid carcinoma: a multicenter cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study.World journal of surgical oncology · 2026Trial
- Poorly differentiated thyroid carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Machine learning prediction of overall survival in patients with cT1b renal cell carcinoma after surgical resection using the SEER database.Scientific reports · 2025Article
- Immunophenotypic Panel for Comprehensive Characterization of Aggressive Thyroid Carcinomas.Cells · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Poorly differentiated thyroid cancer (PDTC) is a rare, heterogeneous carcinoma from follicular cells, characterized by poor differentiation, aggressive spread, and poor prognosis. Currently, there is no specific staging system for PDTC. This study aimed to develop a new TNM staging system tailored to PDTC for improved disease management. Methods: A new TNM staging system was designed and internally validated using data from the US SEER database (2004-2016) on PDTC cases. External validation was performed using data from four major institutions in China. Prognostic factors influencing cancer-specific survival (CSS) were identified through Cox regression analyses. Patients were stratified into subgroups based on adjusted hazard ratios (AHRs), weighted by these prognostic factors. The new system classified patients into five stages with distinct 5-year CSS outcomes. Results: The study analyzed 1,201 PDTC cases from SEER and 85 cases from China. Among the 876 patients in the training cohort, the new TNM staging system showed superior discrimination compared to the 8th edition of the AJCC TNM system. The 5-year CSS rates for the new stages I, II, III, IVA, and IVB were 96.3%, 88.4%, 69.4%, 43.3%, and 22.3%, respectively. The new system outperformed the 8th edition in predicting CSS, as shown by time-dependent ROC curves, C-index, and calibration plots. Both internal and external validation confirmed its predictive abilities. Conclusion: The current AJCC staging system inadequately predicts PDTC prognosis. The new TNM staging system developed in this study offers improved stratification and prognosis prediction, potentially guiding more effective clinical management for PDTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.